Navigation Links
Celsis IVT Settles LiverPool Patent Infringement Suit With XenoTech, LLC
Date:5/13/2010

BALTIMORE, May 13 /PRNewswire/ -- Celsis International Ltd. announced today that Celsis In Vitro, Inc. ("Celsis IVT") has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.

The lawsuit involved a patent owned by Celsis IVT relating to processes for producing its LiverPool™ products. The LiverPool products are multi-cryopreserved, pooled hepatocyte products used by pharmaceutical companies to evaluate potential drug compounds.

As part of the settlement agreement, XenoTech has agreed to cease manufacturing and selling its CryoXTreme products. Other terms of the settlement agreement are confidential.

"Celsis believes in the fundamental importance of respecting patents and other forms of intellectual property, and we intend to defend the time and energy we have invested in our LiverPool product line and patents," said Jay LeCoque, CEO of Celsis. "I am pleased that this lawsuit has been settled and that CryoXTreme has been removed from the market."

For more information about Celsis and its products, visit www.celsis.com.

About Celsis IVT

Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit www.celsis.com/ivt for more information.

About Celsis International

Chicago-based Celsis International is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit www.celsis.com.


'/>"/>
SOURCE Celsis International Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Chicago-Based Celsis International Goes Private
3. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
4. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
5. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
6. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
7. Celsis Receives Frost & Sullivan 2008 Best Practices Award
8. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
9. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
10. Advanced Bionics Reaches Resolution With FDA, Settles Financial Suit
11. ADVENTRX Settles Dispute With Former Licensee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):